Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data
ConclusionsThe introduction of CT-P13 and the disruption of patient treatment management were not associated with differences in average outpatient and inpatient costs and length of stay, in contrast to the results reported in the rest of the literature. Future research should focus on the cost-effectiveness of non-medical switching policies and the potential benefits for patients.
Source: Health Economics Review - Category: International Medicine & Public Health Source Type: research
More News: Economics | Gastroenterology | International Medicine & Public Health | Laboratory Medicine | Remicade | Rheumatology | Study | Switzerland Health